New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner

A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is evaluating Rhenium-186 Obisbemeda in patients with recurrent glioblastoma (GBM)—one of the most aggressive and treatment-resistant forms of brain cancer.

The article, titled “Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma,” features a compelling Q&A with Dr. Andrew Brenner, M.D., Ph.D., one of the trial’s principal investigators. Dr. Brenner shares insights on the potential of targeted radiotherapeutics to improve survival outcomes in this high-need patient population.

Read the full article here: Cancer Network

About the ReSPECT-GBM Trial

The ReSPECT-GBM trial is currently enrolling patients and is designed to assess the safety, optimal dosing, and efficacy of Rhenium-186 Obisbemeda delivered directly into the tumor cavity. This novel approach aims to deliver radiation precisely where it is needed most—minimizing systemic exposure while maximizing local tumor control.

For more information or to see if you or someone you know may qualify, visit: respect-trials.com/gbm

At Plus Therapeutics, we remain committed to developing advanced radiotherapeutic solutions that bring new hope to patients facing CNS cancers.

#Glioblastoma #GBM #BrainCancer #RecurrentGBM #Radiotherapeutics #ClinicalTrials #ReSPECTGBM #Oncology #CancerResearch #BrainTumor #PrecisionMedicine #RheniumObisbemeda #TargetedTherapy #PSTV #PlusTherapeutics